Heart failure & cardiomyopathies
Clinical Utility and Safety of Finerenone in Patients with Heart Failure: Rationale and Design of FINE Registry
Study context
- Population
- Patients with previous history of decompensated heart failure (HF) and elevated natriuretic peptides (NPs), irrespective of ejection fraction
- Planned comparison
- Patients initiating finerenone vs 1:1 matched control cohort not receiving finerenone
Methodological detailsincluding regional and tertiary hospitals, 1:1 matched control cohort
- Including regional and tertiary hospitals
- 1:1 matched control cohort
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
- Endpoints will include the incidence of HF exacerbations requiring intravenous therapy, hospitalizations, renal replacement therapy, and mortality due to cardiovascular or renal causes
- Design paper; no results reported
- Study design: follow-up at 6 and 12 months (and optional 3 and 5 years); endpoints include the incidence of HF exacerbations requiring intravenous therapy, hospitalizations, renal replacement therapy, and mortality due to cardiovascular or renal causes
Original publication
Clinical Utility and Safety of Finerenone in Patients with Heart Failure: Rationale and Design of FINE Registry. ESC Heart Fail. Published 28 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →